YUM vs ALNY Comparison

Yum Brands is a US-based restaurant operator featuring a portfolio of four brands: KFC (31,981 global units at year-end 2024), Pizza Hut (20,225 units), Taco Bell (8,757 units), and Habit Burger & Grill (nearly 400 units). With more than $65 billion in 2024 systemwide sales, the firm is the second-largest restaurant company in the world behind McDonald's ($131 billion), ahead of Restaurant Brands International ($44 billion) and Starbucks ($30 billion). Yum is 98% franchised, with the largest franchisee, Yum China, spun out in 2016, after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity. Yum is the newest evolution of Tricon, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.